Dear Friends here is yet another newsletter giving you recent news & happenings in our field.

Statins May Protect Against Memory Loss

People at high risk for dementia who took cholesterol-lowering statins are half as likely to develop dementia as those who do not take statins, a new study shows. Details

Research indicates Tea may improve attention and focus

Drinking four to five cups of tea a day may help maintain a healthy mind and body, according to new research published in a supplement to the August issue of the Journal of Nutrition. Details 

Biogenerics Would Reduce Health Care Costs for Patients, Says GPhA High Health Care Costs the Focus of Joint Economic Committee Hearing

The Generic Pharmaceutical Association (GPhA) today said the availability of a workable pathway that provides timely patient access to safe, affordable and life-saving biogeneric medicines would save consumers and the health care system billions of dollars. Details

Sanofi-aventis to acquire Symbion from Primary Health Care

French pharma company Sanofi-aventis has entered into a binding agreement with Primary Health Care Limited of Sydney, Australia to acquire Symbion CP Holdings in Australia. Details

Bayer's Novel Anticoagulant Rivaroxaban Recommended for Approval in the EU

The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the anticoagulant rivaroxaban (Xarelto®), taken as one tablet, once-daily, for the prevention of venous blood clots in patients undergoing elective (planned) hip or knee replacement surgery. Details

Drug Makers Seek Antiobesity Blockbuster

A handful of drug companies are testing new ways to treat obesity after years of research into the condition have failed to produce a blockbuster for big pharma. Details

Merck puts HIV development program on hold

Canada's Ambrilia Biopharma says that Merck has placed the development program for the HIV therapy--MK-8122--on hold as it focuses on basic science efforts to evaluate other PL-100 prodrugs and formulation options. Ambrilia says that Merck is also exploring possible back-up compounds. Details

Do let me know about your view on this newsletter.